HEPA HEPION PHARMACT
HEPION PHARMACT (HEPA) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Where they traded
Last open-market purchase: August 3, 2026 , by Stetz Gary S. .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| LoPriore Vincent S 2 fills | Executive Chairman | Buy | 10,000,000 | $0.05 | $500.0K | 16,250,000 | |
| Purcell Michael J. | Director | Buy | 2,000,000 | $0.05 | $100.0K | 3,250,000 | |
| Appajosyula Sireesh | Chief Operating Officer | Buy | 2,000,000 | $0.05 | $100.0K | 3,250,000 | |
| Stetz Gary S. | Interim CEO | Buy | 2,000,000 | $0.05 | $100.0K | 3,250,000 | |
| Stetz Gary S. II | Director | Buy | 500,000 | $0.05 | $25.0K | 500,000 | |
| LoPriore Vincent S 2 fills | Executive Chairman | Buy | 6,250,000 | $0.04 | $250.0K | 6,250,000 | |
| Purcell Michael J. | Director | Buy | 1,250,000 | $0.04 | $50.0K | 1,250,000 | |
| Appajosyula Sireesh | Director | Buy | 1,250,000 | $0.04 | $50.0K | 1,250,000 | |
| Stetz Gary S. | Interim CEO | Buy | 1,250,000 | $0.04 | $50.0K | 1,250,000 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.